0 619

Cited 30 times in

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin

 Chansoo Moon  ;  Kyu Sik Jung  ;  Do Young Kim  ;  Oidov Baatarkhuu  ;  Jun Yong Park  ;  Beom Kyung Kim  ;  Seung Up Kim  ;  Sang Hoon Ahn  ;  Kwang-Hyub Han 
 DIGESTIVE DISEASES AND SCIENCES, Vol.60(2) : 573-581, 2015 
Journal Title
Issue Date
Adult ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use* ; Biomarkers/blood ; Carcinoma, Hepatocellular/diagnosis ; Carcinoma, Hepatocellular/epidemiology ; Carcinoma, Hepatocellular/prevention & control* ; Carcinoma, Hepatocellular/virology ; Chi-Square Distribution ; Disease Progression ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/drug effects ; Hepacivirus/genetics ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy* ; Humans ; Incidence ; Interferon-alpha/adverse effects ; Interferon-alpha/therapeutic use* ; Kaplan-Meier Estimate ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/epidemiology ; Liver Cirrhosis/prevention & control* ; Liver Cirrhosis/virology ; Liver Neoplasms/diagnosis ; Liver Neoplasms/epidemiology ; Liver Neoplasms/prevention & control* ; Liver Neoplasms/virology ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Odds Ratio ; Polyethylene Glycols/adverse effects ; Polyethylene Glycols/therapeutic use* ; Protective Factors ; RNA, Viral/blood ; Recombinant Proteins/adverse effects ; Recombinant Proteins/therapeutic use ; Republic of Korea/epidemiology ; Retrospective Studies ; Ribavirin/adverse effects ; Ribavirin/therapeutic use* ; Risk Factors ; Time Factors ; Treatment Outcome ; Viral Load
Hepatitis C ; Cirrhosis ; Hepatocellular carcinoma ; Antiviral therapy ; Sustained virological response
BACKGROUND: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients

METHODS: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of cirrhosis-related complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis, and development of hepatocellular carcinoma (HCC).

RESULTS: Three hundred patients achieved SVR, and 163 were classified into the non-SVR group. The overall SVR rates were 64.8 %, and multivariate analysis showed that younger age, non-cirrhosis, HCV genotype 2 or 3, lower HCV RNA level (<800,000 IU/mL), and lower body weight were independent factors associated with SVR (all P < 0.05). During a median follow-up of 36.1 months, non-cirrhotic patients with SVR had significantly lower risk of progression to cirrhosis compared with patients with non-SVR (P < 0.001). Moreover, SVR was related to a reduced risk of HCC development (P = 0.017).

CONCLUSIONS: SVR resulted in significantly more favorable long-term outcomes, such as lower risk of progression to cirrhosis and HCC occurrence compared with non-SVR.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Kim, Beom Kyung(김범경) ORCID logo https://orcid.org/0000-0002-5363-2496
Kim, Seung Up(김승업) ORCID logo https://orcid.org/0000-0002-9658-8050
Moon, Chan Soo(문찬수)
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Jung, Kyu Sik(정규식)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.